Extended Data Figure 2: Tumour growth of genetically engineered mice.
From: Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
a, Overall survival of all three models: BrafV600E/Pten−/− with 100% lethality and mean time to death of 31 days (n = 14), BrafV600E/CAT-STA with 85% lethality and mean time to tumour event of 93 days (n = 8), and BrafV600E/Pten−/−/CAT-STA with 100% lethality and mean time to tumour event of 36 days (n = 14). b, Tumour outgrowth of BrafV600E/Pten−/− (red) and BrafV600E/Pten−/−/CAT-STA (blue) tumours shown as mm3 at days after tamoxifen application (n = 10). c, Representative macroscopic pictures for tumour growth over time when tamoxifen was applied on the lower back of the mouse (see illustration). d, Gene array analysis of tumours isolated from GEMs (n = 4, Mann–Whitney U test). e, Histology slides showing representative examples for haematoxylin and eosin stain in all three mouse models (left, ×20, scale bars indicate 100 μm; right, ×100, scale bars indicate 20 μm). *P ≤ 0.05; NS, not significant.
